Replicor announces transition of REP 2139-Mg to subcutaneous administration at AASLD 2021
MONTREAL, November 1st, 2021 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced four abstracts accepted for presentation at the 2021 meeting of the American Association for the Study of the Liver (AASLD) to be held virtually November 12-16, 2021.
Transition of REP 2139-Mg to subcutaneous administration (late breaking poster LB-14)
Compassionate use of TDF, low dose (90ug) pegIFN and subcutaneously administered REP 2139-Mg in a cirrhotic patient with chronic HBV / HDV co-infection was supervised by Dr. Marc Bourlière at the Hôpital Saint Joseph (Marseille, France). REP 2139-Mg administration was well tolerated, and the combination therapy was accompanied by similar potent antiviral response (rapid HBsAg loss and seroconversion, HDV RNA loss and therapeutic transaminase flare) as observed in previous clinical trials with intravenous infusion of REP 2139-Mg.
Rapid HBsAg clearance with NAPs is associated with establishment of functional cure (poster 840)
A Presidential poster of distinction, this analysis of HBsAg kinetics during the REP 401 study is part of an ongoing collaboration with the lab of Dr. Harel Dahari (Loyola University, Chicago) demonstrating that rapid monophasic decline in HBsAg early in NAP-based combination therapy predicts functional cure.
Effects of TDF monotherapy on cccDNA (Poster 805)
Performed in collaboration with the lab of Dr. Harel Dahari and Abbot Diagnostics, analysis of HBV RNA, HBcrAg and ALT demonstrate reduction of cccDNA function during TDF monotherapy in the REP 401 study.
Further elucidation of the intracellular target interaction of NAPs with DNAJB12 (poster 836).
Ongoing studies performed in collaboration with the lab of Dr. Patrick Labonté (INRS Institute ArmandFrappier, Laval, Canada) demonstrate the pH sensitive interaction of NAPs with DNAJB12 consistent with the inhibition of subviral particle assembly of NAPs within the ERGIC.
Dr. Andrew Vaillant, CSO of Replicor commented, “Our first initial clinical use of REP 2139-Mg by subcutaneous administration performed as expected and its well tolerated nature paves the way for the transition of REP 2139-Mg to subcutaneous administration in all future clinical studies”.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com